{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["8(11)"],"submitter":["Gallegos AC"],"pubmed_abstract":["Objective: There are no safety or absorption studies to guide topical timolol therapy for treatment of chronic wounds. This study was undertaken to address this gap. Approach: A prospective, observational, cross-sectional comparative study of timolol plasma levels in patients after topical administration to a chronic wound, compared with levels in patients after timolol ocular administration for the indication of glaucoma. Results: There was no statistically significant difference in the average plasma level of timolol in wound as compared with glaucoma patients. No bradycardia or wheezing was observed after administration. Innovation: We determined the single time point concentration of timolol in plasma 1 h after application of timolol 0.5% gel-forming solution to debrided chronic wounds"],"journal":["Advances in wound care"],"pagination":["538-545"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6798797"],"repository":["biostudies-literature"],"pubmed_title":["Absorption and Safety of Topically Applied Timolol for Treatment of Chronic Cutaneous Wounds."],"pmcid":["PMC6798797"],"pubmed_authors":["West K","Peavy TR","Dixon RW","Isseroff RR","Tchanque-Fossuo CN","Patel RP","Gallegos AC","Dahle SE","Davis MJ","Eisentrout-Melton A"],"additional_accession":[]},"is_claimable":false,"name":"Absorption and Safety of Topically Applied Timolol for Treatment of Chronic Cutaneous Wounds.","description":"Objective: There are no safety or absorption studies to guide topical timolol therapy for treatment of chronic wounds. This study was undertaken to address this gap. Approach: A prospective, observational, cross-sectional comparative study of timolol plasma levels in patients after topical administration to a chronic wound, compared with levels in patients after timolol ocular administration for the indication of glaucoma. Results: There was no statistically significant difference in the average plasma level of timolol in wound as compared with glaucoma patients. No bradycardia or wheezing was observed after administration. Innovation: We determined the single time point concentration of timolol in plasma 1 h after application of timolol 0.5% gel-forming solution to debrided chronic wounds","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Nov","modification":"2025-04-26T16:49:39.569Z","creation":"2019-11-05T08:08:00Z"},"accession":"S-EPMC6798797","cross_references":{"pubmed":["31637100"],"doi":["10.1089/wound.2019.0970"]}}